Evidence map›Paper›PMID 28212496›Full record

ReviewCanadian journal of psychiatry. Revue canadienne de psychiatrie2017

Antipsychotic Use in Dementia.

Julia Kirkham, Chelsea Sherman, Clive Velkers, Colleen Maxwell, Sudeep Gill, Paula Rochon, Dallas Seitz

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Article
  10. Article
  11. Review
  12. Identifying dementia neuropathology using low-burden clinical data.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Julia Kirkham1 Department of Psychiatry, Queen's University, Kingston, Ontario.
Chelsea Sherman1 Department of Psychiatry, Queen's University, Kingston, Ontario.
Clive Velkers1 Department of Psychiatry, Queen's University, Kingston, Ontario.
Colleen Maxwell2 Schools of Pharmacy and Public Health & Health Systems, University of Waterloo, Waterloo, Ontario.
Sudeep Gill3 Division of Geriatric Medicine, Department of Medicine, Queen's University, Kingston, Ontario.
Paula Rochon4 Women's College Research Institute, Women's College Hospital, Toronto, Ontario.
Dallas Seitz1 Department of Psychiatry, Queen's University, Kingston, Ontario.

Funding

CIHR
6 · The paper itself

Abstract

Antipsychotics are necessary for many older adults to treat major mental illnesses or reduce distressing psychiatric symptoms. Current controversy exists over the role of antipsychotics in the management of neuropsychiatric symptoms (NPS) in persons with dementia. Although some NPS may be appropriately and safely treated with antipsychotics, a fine balance must be achieved between the benefits of these medications, which are often modest, and adverse events, which may have significant consequences. Approximately one-third of all persons with dementia are currently prescribed antipsychotic medications, and there is significant variation in the use of antipsychotics across care settings and providers. Reducing the inappropriate or unnecessary use of antipsychotics among persons with dementia has been the focus of increasing attention owing to better awareness of the potential problems associated with these medications. Several approaches can be used to curb the use of antipsychotics among persons with dementia, including policy or regulatory changes, public reporting, and educational outreach. Recently, there has been encouraging evidence of a downward trend in the use of antipsychotics in many long-term care settings, although prescribing rates are still higher than what is likely optimal. Although reducing the inappropriate use of antipsychotics is a complex task, psychiatrists can play an important role via the provision of clinical care and research evidence, contributing to improved care of persons with dementia in Canada and elsewhere.

Indexed as

Antipsychotic AgentsDementiaDrug PrescriptionsHumansAntipsychotic Agentsadverse eventsantipsychoticsdementialong-term carequality improvementquality of care

Identifiers

PMID28212496
PMCPMC5317021

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.